1392 related articles for article (PubMed ID: 15805381)
1. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome.
Sinha SK; Lacaze-Masmonteil T; Valls i Soler A; Wiswell TE; Gadzinowski J; Hajdu J; Bernstein G; Sanchez-Luna M; Segal R; Schaber CJ; Massaro J; d'Agostino R;
Pediatrics; 2005 Apr; 115(4):1030-8. PubMed ID: 15805381
[TBL] [Abstract][Full Text] [Related]
2. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants.
Moya FR; Gadzinowski J; Bancalari E; Salinas V; Kopelman B; Bancalari A; Kornacka MK; Merritt TA; Segal R; Schaber CJ; Tsai H; Massaro J; d'Agostino R;
Pediatrics; 2005 Apr; 115(4):1018-29. PubMed ID: 15805380
[TBL] [Abstract][Full Text] [Related]
3. One-year follow-up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter randomized, controlled trials.
Moya F; Sinha S; Gadzinowski J; D'Agostino R; Segal R; Guardia C; Mazela J; Liu G;
Pediatrics; 2007 Jun; 119(6):e1361-70. PubMed ID: 17533176
[TBL] [Abstract][Full Text] [Related]
4. Acute and sustained effects of lucinactant versus poractant-alpha on pulmonary gas exchange and mechanics in premature lambs with respiratory distress syndrome.
Gastiasoro-Cuesta E; Alvarez-Diaz FJ; Rey-Santano C; Arnaiz-Renedo A; Loureiro-Gonzalez B; Valls-i-Soler A
Pediatrics; 2006 Feb; 117(2):295-303. PubMed ID: 16452346
[TBL] [Abstract][Full Text] [Related]
5. A pilot randomized, controlled trial of later treatment with a peptide-containing, synthetic surfactant for the prevention of bronchopulmonary dysplasia.
Laughon M; Bose C; Moya F; Aschner J; Donn SM; Morabito C; Cummings JJ; Segal R; Guardia C; Liu G;
Pediatrics; 2009 Jan; 123(1):89-96. PubMed ID: 19117865
[TBL] [Abstract][Full Text] [Related]
6. Lucinactant for the prevention of respiratory distress syndrome in premature infants.
Jordan BK; Donn SM
Expert Rev Clin Pharmacol; 2013 Mar; 6(2):115-21. PubMed ID: 23473590
[TBL] [Abstract][Full Text] [Related]
7. Pulmonary distribution of lucinactant and poractant alfa and their peridosing hemodynamic effects in a preterm lamb model of respiratory distress syndrome.
Terry MH; Merritt TA; Harding B; Schroeder H; Merrill-Henry J; Mazela J; Gregory TJ; Segal R; Power GG; Blood AB
Pediatr Res; 2010 Sep; 68(3):193-8. PubMed ID: 20531255
[TBL] [Abstract][Full Text] [Related]
8. Poractant alfa and beractant treatment of very premature infants with respiratory distress syndrome.
Fujii AM; Patel SM; Allen R; Doros G; Guo CY; Testa S
J Perinatol; 2010 Oct; 30(10):665-70. PubMed ID: 20336076
[TBL] [Abstract][Full Text] [Related]
9. Lucinactant: in neonatal respiratory distress syndrome.
Moen MD; Perry CM; Wellington K
Treat Respir Med; 2005; 4(2):139-45; discussion 146-7. PubMed ID: 15813666
[TBL] [Abstract][Full Text] [Related]
10. Surfactant respiratory therapy using Surfaxin/sinapultide.
Lal MK; Sinha SK
Ther Adv Respir Dis; 2008 Oct; 2(5):339-44. PubMed ID: 19124381
[TBL] [Abstract][Full Text] [Related]
11. Protein containing synthetic surfactant versus animal derived surfactant extract for the prevention and treatment of respiratory distress syndrome.
Pfister RH; Soll RF; Wiswell T
Cochrane Database Syst Rev; 2007 Jul; (3):CD006069. PubMed ID: 17636826
[TBL] [Abstract][Full Text] [Related]
12. Patent ductus arteriosus hemodynamics in very premature infants treated with poractant alfa or beractant for respiratory distress syndrome.
Fujii A; Allen R; Doros G; O'Brien S
J Perinatol; 2010 Oct; 30(10):671-6. PubMed ID: 20336077
[TBL] [Abstract][Full Text] [Related]
13. A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants.
Ramanathan R; Rasmussen MR; Gerstmann DR; Finer N; Sekar K;
Am J Perinatol; 2004 Apr; 21(3):109-19. PubMed ID: 15085492
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of surfactant-TA, calfactant and poractant alfa for preterm infants with respiratory distress syndrome: a retrospective study.
Jeon GW; Oh M; Sin JB
Yonsei Med J; 2015 Mar; 56(2):433-9. PubMed ID: 25683992
[TBL] [Abstract][Full Text] [Related]
15. Protein containing synthetic surfactant versus animal derived surfactant extract for the prevention and treatment of respiratory distress syndrome.
Pfister RH; Soll RF; Wiswell T
Cochrane Database Syst Rev; 2007 Oct; (4):CD006069. PubMed ID: 17943881
[TBL] [Abstract][Full Text] [Related]
16. A pilot, randomized, controlled clinical trial of lucinactant, a peptide-containing synthetic surfactant, in infants with acute hypoxemic respiratory failure.
Thomas NJ; Guardia CG; Moya FR; Cheifetz IM; Markovitz B; Cruces P; Barton P; Segal R; Simmons P; Randolph AG;
Pediatr Crit Care Med; 2012 Nov; 13(6):646-53. PubMed ID: 22791092
[TBL] [Abstract][Full Text] [Related]
17. Synthetic Surfactant CHF5633 Compared with Poractant Alfa in the Treatment of Neonatal Respiratory Distress Syndrome: A Multicenter, Double-Blind, Randomized, Controlled Clinical Trial.
Ramanathan R; Biniwale M; Sekar K; Hanna N; Golombek S; Bhatia J; Naylor M; Fabbri L; Varoli G; Santoro D; Del Buono D; Piccinno A; Dammann CE
J Pediatr; 2020 Oct; 225():90-96.e1. PubMed ID: 32553868
[TBL] [Abstract][Full Text] [Related]
18. The short-term outcome of a large cohort of very preterm infants treated with poractant alfa (Curosurf) for respiratory distress syndrome. A postmarketing phase IV study.
Lamboley-Gilmert G; Lacaze-Masmonteil T;
Paediatr Drugs; 2003; 5(9):639-45. PubMed ID: 12956620
[TBL] [Abstract][Full Text] [Related]
19. A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome.
Hudak ML; Martin DJ; Egan EA; Matteson EJ; Cummings NJ; Jung AL; Kimberlin LV; Auten RL; Rosenberg AA; Asselin JM; Belcastro MR; Donohue PK; Hamm CR; Jansen RD; Brody AS; Riddlesberger MM; Montgomery P
Pediatrics; 1997 Jul; 100(1):39-50. PubMed ID: 9200358
[TBL] [Abstract][Full Text] [Related]
20. Effect of two different early rescue surfactant treatments on mortality in preterm infants with respiratory distress syndrome.
Kadıoğlu Şimşek G; Kanmaz Kutman HG; Canpolat FE; Oğuz ŞS
Clin Respir J; 2020 Mar; 14(3):285-290. PubMed ID: 31814293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
